Skip to content

CNS Infection

source:: Pocket Medicine, 2022

ACUTE BACTERIAL MENINGITIS

Definition

  • Inflammation of tissue around the brain/spinal cord
  • Usually arising from nasopharynx (hematogenous spread), bacteremia, or direct inoculation (surgery, contiguous infection, trauma, foreign body [eg, CSF shunt])

Microbiology in Bacterial Meningitis (NEJM 2011;364:2016)

Pathogen
S. pneumoniae (30-60%) Look for preceding infection (bacteremia, pneumonia, endocarditis)

Drug-resistant S. pneumoniae:
˜40% PCN-resistant (even intermediate resistance problematic)
˜<10% 3rd-gen. cephalosporin-resistant
N. meningitidis (10-35%) Primarily in age <30 y; associated petechiae or purpura

↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated

Vaccine rec for all age 11-18 y, HIV infection, asplenia, C5-9 deficiency
H. influenzae (<5%) ↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated, CSF leak, trauma/surgery, mastoiditis

Vaccine rec for all children; markedly ↓ incidence
L. monocytogenes (5-10%) ↑ in immunosupp (glucocorticoids, transplant), elderly, malignancy, pregnant, cirrhosis. Outbreaks a/w contaminated dairy & raw veg.
GNBs (1-10%) More common in health care associated meningitis (E. coli, Klebsiella sp., Pseudomonas aeruginosa)
Staphylococci (5%) Preceding infection (endocarditis, bacteremia), post CNS surgery, foreign bodies (CSF) shunt, intrathecal pump)
Mixed infection Suspect parameningeal focus or CSF leak, post CNS surgery
### Clinical manifestations (Lancet 2016;339:16)
- Headache (84%), fever (74%), stiff neck (74%), photosensitivity, GCS <14 (71%), nausea (62%), seizure (23%); 95% have 2 of 4: HA, fever, stiff neck, ΔMS
- Presentation may be atypical (eg, lethargy w/o fever) in elderly and immunosupp.

Physical exam (CID 2002;35:46; Am J Emerg Med 2013;31:1601)

  • Nuchal rigidity (Se 30%, Sp 68%), Kernig's sign (Se 5%, Sp 95%), Brudzinski's sign (Se 5%, Sp 95%), jolt sign (HA worsens w/ horizontal rotation) (Se 64%, Sp 43%)
  • ± Focal neuro findings (˜30%; hemiparesis, aphasia, visual field cuts, CN palsies)
  • ± HEENT findings: sinus tenderness, clear rhinorrhea (CSF leak)
  • ± Skin and joint findings: petechial rash (N. meningitidis), genital or oral ulcers (HSV), arthritis with joint effusion (N. meningitidis)

Sequential management of bacterial meningitis

  • Blood cx, initiate empiric antibiotics, consider corticosteroids (vide infra)
  • CT head if indicated (see below)
  • LP ASAP (if not contraindicated); yield of CSF cx unlikely to be changed if obtained w/in ˜4 h of initiation of abx

Diagnostic studies (NEJM 2017;388:3036)

  • Blood cultures ×2 before abx
  • WBC count: >10,000 in >90% of bacterial meningitis in healthy hosts
  • Head CT to r/o mass effect before LP if ≥1 high-risk feature: immunosupp., h/o CNS disease, new-onset seizure, focal neuro findings, papilledema, GCS <15 (CID 2004;39:1267)
  • Lumbar puncture with opening pressure (NEJM 2006;355:e12)
  • Send CSF for cell count and differential, glucose, protein, Gram stain, bacterial cx
  • Additional CSF studies based on clinical suspicion: AFB smear/cx (or MTb PCR), cryptococcal Ag, fungal cx, VDRL, PCR (HSV, VZV, enteroviral), cytology
  • CSF Gram stain has 30-90% Se; cx 80-90% Se if LP done prior to abx though abx should not be delayed for LP if there is concern for bacterial meningitis
  • Rule of 2s: CSF WBC >2k, gluc <20, TP >200 has >98% Sp for bacterial meningitis
  • Repeat LP only if no clinical response after 48 h of appropriate abx or CSF shunt
  • Metagenomic next-generation sequencing ↑ dx yield (NEJM 2019;380:2327)

Typical CSF Findings in Meningitis

Type Appearance Pressure (cm H2O) WBC/mm3 Predom Type Glc (mg/dL) TP (mg/dL)
Normal Clear 9-18 0-5 lymphs 50-75 15-40
Bacterial Cloudy 18-30 100-10,000 polys <45 100-1000
TB Cloudy 18-30 <500 lymphs <45 100-200
Fungal Cloudy 18-30 <300 lymphs <45 40-300
Aseptic Clear 9-18 <300 polys → lymphs 50-100 50-100
### Empiric Treatment of Bacterial Meningitis (Lancet 2012;380:1693)
Adults <50 y Ceftriaxone + vancomycin (trough 15-20), consider acyclovir IV
Adults >50 y Ceftriaxone + vancomycin + ampicillin, consider acyclovir IV
Immunosuppressed [Cefepime or meropenem] + vanc ± amp (not nec. if on meropenem), consider acyclovir IV & fungal coverage
Healthcare assoc. infection (eg, surgery, CSF shunt) [Cefepime or meropenem or ceftazidime] + vancomycin
- When possible, organism-directed Rx, guided by sensitivities or local patterns of drug resistance should be used
- Confirm appropriate dosing as higher doses are often needed in meningitis (though may need to be adjusted for renal function)
- Corticosteroids: If causative organism is unknown, dexamethasone 10 mg IV q6h × 4 d recommended prior to or with initiation of abx. Greatest benefit in S. pneumoniae and GCS 8-11 (↓ neuro disability & mortality by ˜50%). Avoid in crypto (NEJM 2016;374:542).
- Prophylaxis: for close contacts of Ptw/N. meningitidis; rifampin (600 mg PO bid × 2 d) or ciprofloxacin (500 mg PO × 1) or ceftriaxone (250 mg IM × 1).
- Precautions: droplet precautions until N. meningitidis is ruled out

ASEPTIC MENINGITIS

Definition

  • Clinical/lab evidence of meningeal inflammation with negative bacterial cx (CSF & blood)

Etiologies (Neurology 2006;66:75)

  • Viral: enteroviruses are most common cause (summer/fall; rash, GI, URI sx), HIV, HSV, VZV, mumps (parotitis), lymphocytic choriomeningitis virus (rodent exposure), encephalitis viruses, adenovirus, polio, CMV, EBV, WNV
  • Focal bacterial infection: brain/epidural/subdural abscess, CNS septic thrombophlebitis
  • Partially treated bacterial meningitis
  • Other infectious: TB, fungal (cryptococcus, coccidiodes), Lyme, syphilis, leptospirosis
  • Neoplasm: intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis
  • Drug-induced meningitis: NSAIDs, IVIG, antibiotics (TMP-SMX, PCN), anti-epileptics
  • Systemic autoimmune illness: SLE, sarcoidosis, Behçet's, Sjögren's syndrome, RA
  • Mollaret's: recurrent lymphocytic meningitis, spontaneously resolving (often HSV-2)

Diagnosis

  • Obtain LP for CSF analysis: lymphocytic pleocytosis common in viral etiologies (see Typical CSF Findings in Meningitis table above)
  • Consider CSF cytology and MRI brain/spine to evaluate for malignancy
  • Consider serum autoimmune and serum viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric treatment

Empiric treatment

  • Suspected bacterial meningitis: see empiric treatment of bacterial meningitis above
  • Suspected viral meningitis: if concern for HSV meningoencephalitis → IV acyclovir
  • Unclear etiology: consider initiation of empiric bacterial meningitis treatment while observing and awaiting CSF studies

ENCEPHALITIS (NEJM 2018;379:557)

Definition

  • Inflammation of brain parenchyma characterized by impaired cerebral function (AMS, neurologic deficits) often due to primary viral infection or post-viral inflammation

Etiologies (specific etiology found in <20% of cases; Neurology 2006;66:75; CID 2008;47:303)

  • HSV-1 all ages/seasons. If sxs recur after Rx, consider viral relapse vs. autoimmune encephalitis b/c high rates of autoimmune disease wks later (Lancet Neurol 2018;17:760)
  • VZV 1° or reactivation; ± vesicular rash; all ages (favors elderly), all seasons
  • Arboviruses: evaluate for exposure to vector/geography. Mosquitoes: West Nile, Eastern/Western equine, St. Louis, La Crosse; Ixodes tick: Powassan.
  • Enteroviruses (coxsackie, echo): preceding URI/ GI sx; peaks in late summer/early fall
  • Other infectious: CMV, EBV, HIV, JC, measles, mumps, rabies, adeno, influenza, Lyme
  • Non-infectious: autoimmune/paraneoplastic (anti-NMDAR, anti-Hu, anti-Ma2, anti-CRMP5, anti-mGluR5), post-infxn demyelination (eg, ADEM)

Clinical manifestations

  • Fever + ΔMS (subtle to severe), seizure, focal neuro deficit, HA in meningoencephalitis

Diagnostic studies (CID 2013;57:1114)

  • CSF analysis: lymphocytic pleocytosis; PCR for HSV (95% Se & Sp), VZV; consider other PCR based on risk factors (CMV/EBV, HIV, JC, adeno/enterovirus, WNV)
  • Consider testing for autoimmune etiologies and serologic viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric HSV/VZV Rx
  • MRI (CT if unavailable); HSV temporal lobe; W. Nile & Powassan thalamic hyperintensity
  • EEG to r/o seizure; findings in encephalitis are nonspecific (temporal lobe focus in HSV)

Treatment

  • HSV/VZV: IV acyclovir 10 mg/kg IV q8h; consider empiric treatment given frequency

BELL'S PALSY

Definition & clinical manifestations

  • Acute idiopathic unilat. facial nerve palsy (CN VII), often presumed HSV reactivation
  • P/w unilateral facial muscle weakness, hyperacusis, ↓ taste, lacrimation, & salivation
  • Risk factors: pregnancy (preeclampsia), obesity, HTN, diabetes, preceding URI

Diagnosis (Otol Head Neck Surg 2013;149:656)

  • Labs, imaging, EMG not needed in routine cases
  • Ddx: Bilateral: Lyme, GBS, sarcoid. Additional neuro sx: stroke, tumor. Rash: herpes zoster. Other: otitis media, HIV, Sjögren.

Treatment and Prognosis (CMAJ 2014;186:917)

  • 70% recover spontaneously w/in 6 mos, >80% recover with glucocorticoid treatment
  • Oral corticosteroids started w/in 72 hrs of sx onset improve odds of recovery; dose varies based on severity (House-Brackmann grading). No conclusive data on antivirals.
  • If eyelid closure is compromised, eye protection is crucial to prevent trauma

HERPES ZOSTER (SHINGLES)

Definition & etiology

  • Painful vesicular rash in a peripheral nerve distribution due to reactivation of VZV
  • Spread by contact with active lesion (prior to crusting) in uncomplicated zoster or via airborne transmission in disseminated zoster

Clinical manifestations & complications

  • Uncomplicated: pain in a dermatomal distribution → dermatomal eruption of erythematous papules → vesicles → crusted plaques in varying stages of evolution
  • Disseminated: vesicles across multiple dermatomes, visceral organ involvement (pneumonia, hepatitis, CNS) seen in immunosupp. (eg, transplant, malignancy)
  • Zoster opthalmicus: ocular involvement (V1 of CN V) requires urgent ophtho eval
  • Post-herpetic neuralgia: neuropathic pain lasting >90 d after dx

Diagnosis

  • Clinical diagnosis if uncomplicated
  • Confirm with PCR (most sensitive), DFA, and viral culture (allows for resistance testing) of vesicular fluid (scrape from unroofed vesicle)

Treatment & prevention

  • Uncomplicated: acyclovir, valacyclovir, or famciclovir x 7 d; initiate w/in 72 h of onset for greatest benefit; consider after 72 h if new lesions present; minimal benefit after crusting
  • Superimposed bacterial cellulitis is common; if suspected, treat with appropriate antibiotics
  • Disseminated/immunosupp.: IV acyclovir, eval for visceral spread, droplet precautions
  • Prevention: Shingrix (2 doses) for all Pts >50; consider in younger if immunosupp.